» Articles » PMID: 23020931

Treatment Options for Diabetes: Potential Role of Stem Cells

Overview
Specialty Endocrinology
Date 2012 Oct 2
PMID 23020931
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

There are diseases and injuries in which a patient's cells or tissues are destroyed that can only be adequately corrected by tissue or organ transplants. Stem cells may be able to generate new tissue and even cure diseases for which there is no adequate therapy. Type 1 diabetes (T1DM), an insulin-dependent diabetes, is a chronic disease affecting genetically predisposed individuals, in which insulin-secreting beta (β)-cells within pancreatic islets of Langerhans are selectively and irreversibly destroyed by autoimmune assault. Type 2 diabetes (T2DM) is characterized by a gradual decrease in insulin sensitivity in peripheral tissues and the liver (insulin resistance), followed by a gradual decline in β-cell function and insulin secretion. Successful replacing of damaged β-cells has shown considerable potential in treating T1DM, but lack of adequate donors is a barrier. The literature suggests that embryonic and adult stem cells are promising alternatives in long-term treatment of diabetes. However, any successful strategy should address both the need for β-cell replacement and controlling the autoimmune response to cells that express insulin. This review summarizes the current knowledge of options and the potential of stem cell transplantation in diabetes treatment.

Citing Articles

Hypoxia within subcutaneously implanted macroencapsulation devices limits the viability and functionality of densely loaded islets.

Einstein S, Steyn L, Weegman B, Suszynski T, Sambanis A, OBrien T Front Transplant. 2024; 2:1257029.

PMID: 38993891 PMC: 11235299. DOI: 10.3389/frtra.2023.1257029.


Establishment of a diabetes mellitus type 1 model in the common marmoset.

Yuan W, Fukuda S, Inoue T, Okochi H, Sasaki E, Shimoda M Sci Rep. 2019; 9(1):14546.

PMID: 31601983 PMC: 6787219. DOI: 10.1038/s41598-019-51199-5.


Pax4 synergistically acts with Pdx1, Ngn3 and MafA to induce HuMSCs to differentiate into functional pancreatic β-cells.

Zhang T, Wang H, Wang T, Wei C, Jiang H, Jiang S Exp Ther Med. 2019; 18(4):2592-2598.

PMID: 31572507 PMC: 6755441. DOI: 10.3892/etm.2019.7854.


Mechanistic insights into the augmented effect of bone marrow mesenchymal stem cells and thiazolidinediones in streptozotocin-nicotinamide induced diabetic rats.

Hamza A, Fikry E, Abdallah W, Amin A Sci Rep. 2018; 8(1):9827.

PMID: 29959408 PMC: 6026169. DOI: 10.1038/s41598-018-28029-1.


Advances in islet encapsulation technologies.

Desai T, Shea L Nat Rev Drug Discov. 2016; 16(5):338-350.

PMID: 28008169 PMC: 11286215. DOI: 10.1038/nrd.2016.232.